نتایج جستجو برای: avastin

تعداد نتایج: 680  

2011
J. Fernando Arevalo Juan G. Sanchez Andres F. Lasave Lihteh Wu Mauricio Maia Sergio Bonafonte Miguel Brito Arturo A. Alezzandrini Natalia Restrepo Maria H. Berrocal Mario Saravia Michel Eid Farah Jans Fromow-Guerra Virgilio Morales-Canton

This paper demonstrates multiple benefits of intravitreal bevacizumab (IVB) on diabetic retinopathy (DR) including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) at 24 months of followup. This is a retrospective multicenter interventional comparative case series of intravitreal injections of 1.25 or 2.5 mg of bevacizumab for DME, PDR without tractional retinal detachm...

Journal: :Head & neck 2015
Dominik Riss Martin Burian Axel Wolf Veronika Kranebitter Alexandra Kaider Christoph Arnoldner

BACKGROUND The purpose of this study was to investigate the efficacy of bevacizumab ("Avastin") for the treatment of epistaxis in hereditary hemorrhagic telangiectasia (HHT). METHODS In this double blind, placebo controlled trial, 15 adult patients with HHT with a minimum of 2 epistaxis episodes per week were randomized. A history of thromboembolic events or recent or planned surgery led to e...

Journal: :Archivos de la Sociedad Espanola de Oftalmologia 2012
H Fernández Jiménez-Ortiz S Perucho Martinez N Toledano Fernández E Martin Giral

PURPOSE To describe a case series of neovascular glaucoma treated with intracameral bevacizumab prior to filtering surgery. DESIGN Descriptive, retrospective case series. METHODS Five eyes of 5 patients with neovascular glaucoma due to any cause candidates to filtering surgery who had previously received an injection of intracameral bevacizumab (1.25 mg/0.05 ml) as treatment for neovascular...

Journal: :The British journal of ophthalmology 2007
James Raftery Andrew Clegg Jeremy Jones Seng Chuen Tan Andrew Lotery

Two new drugs provide startling benefits in the treatment of age-related macular degeneration (AMD). The clinical and cost effectiveness of ranibizumab (Lucentis) was compared to that of bevacizumab (Avastin), which costs up to 100 times less. A cost effectiveness model was developed to assess the cost per quality adjusted life year (QALY) over 10 years. For predominantly classic AMD, the effic...

Journal: :Investigative ophthalmology & visual science 2008
Stefanie Kaempf Sandra Johnen Anna Katharina Salz Andreas Weinberger Peter Walter Gabriele Thumann

PURPOSE Repetitive intravitreal injections of bevacizumab are a successful treatment option for exudative age-related macular degeneration (AMD). The aim of this study was to evaluate the toxicity of bevacizumab in the adult mammalian neurosensory retina in culture. METHODS Adult porcine neurosensory retinas were cultured adjoined to the retinal pigment epithelium-choroid layer (retina-RPE-ch...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید